The use of statins in hematopoietic stem cell transplantation

Current Stem Cell Research and Therapy

Volumn 4, Issue 4, 2009, Pages 260-265

  Shimabukuro Vornhagen, Alexander ^a   Glossmann, Jan ^a   Liebig, Tanja ^a   Scheid, Christof ^a   Von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BORTEZOMIB; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENALIDOMIDE; PRAVASTATIN; RITUXIMAB; SIMVASTATIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ALLOTRANSPLANTATION; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HEART PROTECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RHABDOMYOLYSIS; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; MICE; THROMBOSIS;

EID: 70350206562     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488809789649250     Document Type: Review

References (67)

1. Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res 2004; 98(2): 119-27.
2. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium 2003; 10(1): 43-7.
3. Szczepanska-Szerej A, Kurzepa J, Wojczal J, Stelmasiak Z. Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Pharmacol Rep 2007; 59(1): 94-7.
4. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblastlike synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006; 33(3): 463-71.
5. Li, JJ, Li YS, Fang CH, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart 2006; 92(4): 529-30.
6. Ghittoni R., Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005; 19(6): 605-7.
7. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003; 108(12): 1506-13.
8. Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110(10): 3804-13.
9. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4(+)-CD25(+) T cells. Atherosclerosis 2008; 197(2): 829-39.
10. Mira E, Leon B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181(5): 3524-34.
11. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285(5426): 412-5.
12. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10(9): 987-92.
13. Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004; 172(1): 85-93.
14. Yilmaz A, Reiss C, Weng A, et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 2006; 79(3): 529-38.
15. Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood 2008; 112(4): 1544-5.
16. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998; 17(4): 335-40.
17. Tanaka T, Porter CM, Horvath-Arcidiacono JA, Bloom ET. Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis. Int Immunol 2007; 19(2): 163-73.
18. Hillyard DZ, Nutt CD, Thomson J, et al. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 2007; 191(2): 319-25.
19. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990; 145(2): 244-52.
20. Vaessen LM, van Miert PP, van Gelder T, Ijzermans JN, Weimar W. Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients. Transplantation 2001; 71(8): 1175-9.
21. Takahashi HK, Mori S, Iwagaki H, et al. Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. Clin Immunol 2005; 116(3): 211-6.
22. Takahashi HK, Mori S, Iwagaki H, et al. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005; 77(3): 400-7.
23. Takahashi HK, Weitz-Schmidt G, Iwagaki H, et al. Hypothesis: the antitumor activities of statins may be mediated by IL-18. J Leukoc Biol 2006; 80(2): 215-6.
24. Reddy P, Teshima T, Hildebrandt G, et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood 2002; 100(9): 3429-31.
25. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2003; 101(7): 2877-85.
26. Min CK, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediate by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 2004; 104(10): 3393-9.
27. Arnold D, Wasem C, Juillard P, et al. IL-18-independent cytotoxic T lymphocyte activation and IFN-gamma production during experimental acute graft-versus-host disease. Int Immunol 2002; 14(5): 503-11.
28. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194(10): 1433-40.
29. Okamoto I, Kohno K, Tanimoto T, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol 2000; 164(11): 6067-74.
30. Facon T, Jouet JP, Noel-Walter MP, et al. Involvement of TNFalpha secreting macrophages in lethal forms of human graft-versushost disease. Bone Marrow Transplant 1997; 20(6): 511-5.
31. Broz P, Ben-Haim N, Grzelakowski M, et al. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesiclebased drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008; 51(3): 246-52.
32. Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol 2006; 33(12): 1144-9.
33. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2008.
34. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110(13): 4588-98.
35. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versushost disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008; 111(7): 3901-2.
36. Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005; 79(3): 372-4.
37. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 356(9234): 993-7.
38. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007; 110(9): 3463-71.
39. Gerber DE, Segal JB, Levy MY, et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112(3): 504-10.
40. Gonsalves A, Carrier M, Wells PS, et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6(9): 1468-73.
41. Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res 2008; 122(3): 314-9.
42. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospitalbased case-control study. Fundam Clin Pharmacol 2004; 18(4): 477-82.
43. van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61(11): 957-61.
44. Coleman CI, Lucek DM, Hammond J, White CM. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007; 23(8): 1783-90.
45. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31(3): 611-7.
46. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005; 6: 82.
47. Hackam DG, M Mamdani, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367(9508): 413-8.
48. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110(7): 880-5.
49. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008; 61(2): 362-4.
50. Fortuny J, de Sanjose S, Becker N, et al. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 2006; 15(5): 921-5.
51. Burke LP, Kukoly CA. Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours. Leuk Lymphoma 2008; 49(2): 322-30.
52. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101(9): 3628-34.
53. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007; 67(9): 4524-32.
54. van de Donk NW, Schotte D, Kamphuis MM, et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 2003; 9(15): 5735-48.
55. von Tresckow B, von Strandmann EP, Sasse S, et al. Simvastatindependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. Haematologica 2007; 92(5): 682-5.
56. Katano H., Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004; 101(14): 4960-5.
57. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001; 1(2): 141-9.
58. van der Spek E, Bloem AC, Lokhorst HM, et al. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2008.
59. Calabro A, Tai J, Allen SL, Budman DR. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 2008; 19(7): 705-12.
60. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphatedependent survival pathway. Biochem Biophys Res Commun 2008; 374(2): 309-14.
61. Schmidmaier R, Baumann P, Bumeder I, et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007; 79(3): 240-3.
62. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24(5-6): 533-7.
63. Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109(7): 2999-3006.
64. Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant 2005; 36(8): 739-40.
65. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34(1): 51-61.
66. Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29(3): 235-9.
67. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5(3): e64.